Home/Filings/4/0001415889-25-024295
4//SEC Filing

LaBrosse Nicole 4

Accession 0001415889-25-024295

CIK 0001159036other

Filed

Sep 10, 8:00 PM ET

Accepted

Sep 11, 5:09 PM ET

Size

15.1 KB

Accession

0001415889-25-024295

Insider Transaction Report

Form 4
Period: 2025-09-10
LaBrosse Nicole
SVP, CHIEF FINANCIAL OFFICER
Transactions
  • Exercise/Conversion

    Option to Purchase Common Stock

    2025-09-101,135812 total
    Exercise: $12.49Exp: 2027-08-01Common Stock (1,135 underlying)
  • Exercise/Conversion

    Common Stock

    2025-09-10$12.07/sh+11,271$136,04143,171 total
  • Exercise/Conversion

    Common Stock

    2025-09-10$12.49/sh+1,135$14,17644,306 total
  • Sale

    Common Stock

    2025-09-10$75.93/sh13,240$1,005,30024,306 total
  • Sale

    Common Stock

    2025-09-10$75.29/sh6,760$508,96737,546 total
  • Exercise/Conversion

    Option to Purchase Common Stock

    2025-09-1011,2710 total
    Exercise: $12.07Exp: 2027-02-22Common Stock (11,271 underlying)
Footnotes (5)
  • [F1]The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • [F2]Represents a weighted average sales price per share. These shares were sold at prices ranging from $74.56 to $75.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F3]Represents a weighted average sales price per share. These shares were sold at prices ranging from $75.56 to $76.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F4]This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.
  • [F5]This option was granted on August 1, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Issuer

HALOZYME THERAPEUTICS, INC.

CIK 0001159036

Entity typeother

Related Parties

1
  • filerCIK 0001910662

Filing Metadata

Form type
4
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 5:09 PM ET
Size
15.1 KB